Literature DB >> 28679058

Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.

Andressa Pena1, Ahasanul Kobir1, Dmitry Goncharov1, Akiko Goda2, Tatiana V Kudryashova1, Arnab Ray1, Rebecca Vanderpool3, Jeffrey Baust1, Baojun Chang1, Ana L Mora1,4, John Gorcsan1,2, Elena A Goncharova1,4,5.   

Abstract

Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling, increased pulmonary artery (PA) pressure, right-heart afterload and death. Mechanistic target of rapamycin (mTOR) promotes smooth muscle cell proliferation, survival, and pulmonary vascular remodeling via two functionally distinct mTOR complexes (mTORCs)-1 (supports cell growth) and -2 (promotes cell survival), and dual mTORC1/mTORC2 inhibition selectively induces pulmonary arterial hypertension PA vascular smooth muscle cell apoptosis and reverses pulmonary vascular remodeling. The consequences of mTOR inhibition on right ventricle (RV) morphology and function are not known. Using SU5416/hypoxia rat model of pulmonary hypertension (PH), we report that, in contrast to activation of both mTORC1 and mTORC2 pathways in small remodeled PAs, RV tissues had predominant up-regulation of mTORC1 signaling accompanied by cardiomyocyte and RV hypertrophy, increased RV wall thickness, RV/left ventricle end-diastolic area ratio, RV contractility and afterload (arterial elastance), and shorter RV acceleration time compared with controls. Treatment with mTOR kinase inhibitor, PP242, at Weeks 6-8 after PH induction suppressed both mTORC1 and mTORC2 in small PAs, but only mTORC1 signaling in RV, preserving basal mTORC2-Akt levels. Vehicle-treated rats showed further PH and RV worsening and profound RV fibrosis. PP242 reversed pulmonary vascular remodeling and prevented neointimal occlusion of small PAs, significantly reduced PA pressure and pulmonary vascular resistance, reversed cardiomyocyte hypertrophy and RV remodeling, improved max RV contractility, arterial elastance, and RV acceleration time, and prevented development of RV fibrosis. Collectively, these data show a predominant role of mTORC1 versus mTORC2 in RV pathology, and suggest potential attractiveness of mTOR inhibition to simultaneously target pulmonary vascular remodeling and RV dysfunction in established PH.

Entities:  

Keywords:  mechanistic target of rapamycin complex 1; mechanistic target of rapamycin complex 2; mechanistic target of rapamycin kinase inhibitor; pulmonary hypertension; right ventricle

Mesh:

Substances:

Year:  2017        PMID: 28679058      PMCID: PMC5705904          DOI: 10.1165/rcmb.2016-0364OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  35 in total

Review 1.  mTOR signaling at a glance.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  J Cell Sci       Date:  2009-10-15       Impact factor: 5.285

2.  Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension.

Authors:  Yu-Ping Xie; Biyi Chen; Philip Sanders; Ang Guo; Yue Li; Kathy Zimmerman; Lie-Cheng Wang; Robert M Weiss; Isabella M Grumbach; Mark E Anderson; Long-Sheng Song
Journal:  Hypertension       Date:  2011-12-27       Impact factor: 10.190

3.  Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling.

Authors:  Toshiyuki Yano; Marcella Ferlito; Angel Aponte; Atsushi Kuno; Tetsuji Miura; Elizabeth Murphy; Charles Steenbergen
Journal:  Circ Res       Date:  2014-02-20       Impact factor: 17.367

4.  Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.

Authors:  Amal Houssaini; Shariq Abid; Nathalie Mouraret; Feng Wan; Dominique Rideau; Mirna Saker; Elisabeth Marcos; Claire-Marie Tissot; Jean-Luc Dubois-Randé; Valérie Amsellem; Serge Adnot
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

Review 5.  mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.

Authors:  Elena A Goncharova
Journal:  FASEB J       Date:  2013-01-25       Impact factor: 5.191

6.  Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.

Authors:  Michie Toba; Abdallah Alzoubi; Kealan D O'Neill; Salina Gairhe; Yuri Matsumoto; Kaori Oshima; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-15       Impact factor: 4.733

7.  Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.

Authors:  Dmitry A Goncharov; Tatiana V Kudryashova; Houman Ziai; Kaori Ihida-Stansbury; Horace DeLisser; Vera P Krymskaya; Rubin M Tuder; Steven M Kawut; Elena A Goncharova
Journal:  Circulation       Date:  2013-11-22       Impact factor: 29.690

8.  Nexavar/Stivarga and viagra interact to kill tumor cells.

Authors:  Mehrad Tavallai; Hossein A Hamed; Jane L Roberts; Nichola Cruickshanks; John Chuckalovcak; Andrew Poklepovic; Laurence Booth; Paul Dent
Journal:  J Cell Physiol       Date:  2015-09       Impact factor: 6.384

9.  Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Stephen L Archer; Albert Defelice; Steven Evans; Monica Fiszman; Thomas Martin; Muriel Saulnier; Marlene Rabinovitch; Ralph Schermuly; Duncan Stewart; Hubert Truebel; Gennyne Walker; Kurt R Stenmark
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

10.  The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex.

Authors:  Emily B Heikamp; Chirag H Patel; Sam Collins; Adam Waickman; Min-Hee Oh; Im-Hong Sun; Peter Illei; Archna Sharma; Aniko Naray-Fejes-Toth; Geza Fejes-Toth; Jyoti Misra-Sen; Maureen R Horton; Jonathan D Powell
Journal:  Nat Immunol       Date:  2014-04-06       Impact factor: 25.606

View more
  19 in total

Review 1.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

2.  Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.

Authors:  Yuhu He; Caojian Zuo; Daile Jia; Peiyuan Bai; Deping Kong; Di Chen; Guizhu Liu; Juanjuan Li; Yuanyang Wang; Guilin Chen; Shuai Yan; Bing Xiao; Jian Zhang; Lingjuan Piao; Yanli Li; Yi Deng; Bin Li; Philippe P Roux; Katrin I Andreasson; Richard M Breyer; Yunchao Su; Jian Wang; Ankang Lyu; Yujun Shen; Ying Yu
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

3.  Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.

Authors:  Tatiana V Kudryashova; Swati Dabral; Soni S Pullamsetti; Elena A Goncharova; Sreenath Nayakanti; Arnab Ray; Dmitry A Goncharov; Theodore Avolio; Yuanjun Shen; Analise Rode; Andressa Pena; Lifeng Jiang; Derek Lin; Jeffrey Baust; Timothy N Bachman; Johannes Graumann; Clemens Ruppert; Andreas Guenther; Mario Schmoranzer; Yann Grobs; Sarah Eve Lemay; Eve Tremblay; Sandra Breuils-Bonnet; Olivier Boucherat; Ana L Mora; Horace DeLisser; Jing Zhao; Yutong Zhao; Sébastien Bonnet; Werner Seeger
Journal:  Circ Res       Date:  2022-02-07       Impact factor: 17.367

4.  A wrinkle in time: circadian biology in pulmonary vascular health and disease.

Authors:  Andrew J Bryant; Elnaz Ebrahimi; Amy Nguyen; Christopher A Wolff; Michelle L Gumz; Andrew C Liu; Karyn A Esser
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-01       Impact factor: 5.464

Review 5.  Emerging therapeutics in pulmonary hypertension.

Authors:  Matthew K Hensley; Andrea Levine; Mark T Gladwin; Yen-Chun Lai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-01       Impact factor: 5.464

6.  Inhibition of mTOR by rapamycin does not improve hypoxic pulmonary hypertension-induced right heart failure in old mice.

Authors:  Benjamin D McNair; Jacob A Schlatter; Ross F Cook; Musharraf Yusifova; Danielle R Bruns
Journal:  Exp Gerontol       Date:  2021-05-07       Impact factor: 4.253

7.  Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer.

Authors:  Danchen Wu; Asish Dasgupta; Austin D Read; Rachel E T Bentley; Mehras Motamed; Kuang-Hueih Chen; Ruaa Al-Qazazi; Jeffrey D Mewburn; Kimberly J Dunham-Snary; Elahe Alizadeh; Lian Tian; Stephen L Archer
Journal:  Free Radic Biol Med       Date:  2021-01-12       Impact factor: 8.101

8.  Inhibition of the mTOR Pathway Exerts Cardioprotective Effects Partly through Autophagy in CLP Rats.

Authors:  Wen Han; Hao Wang; Longxiang Su; Yun Long; Na Cui; Dawei Liu
Journal:  Mediators Inflamm       Date:  2018-06-28       Impact factor: 4.711

9.  Alpha-enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK-Akt pathway.

Authors:  Jingbo Dai; Qiyuan Zhou; Jiwang Chen; Megan L Rexius-Hall; Jalees Rehman; Guofei Zhou
Journal:  Nat Commun       Date:  2018-09-21       Impact factor: 14.919

10.  Inhibitory Antibodies against Activin A and TGF-β Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension.

Authors:  Tatiana V Kudryashova; Yuanjun Shen; Andressa Pena; Emily Cronin; Evelyn Okorie; Dmitry A Goncharov; Elena A Goncharova
Journal:  Int J Mol Sci       Date:  2018-09-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.